Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
Hs 578T Tivantinib
0.031623
MET
RTK
 1.0860 0.00272
HCC1806 Cediranib
0.001
VEGFR/cKIT
RTK
 0.9923 0.00046
Hs 578T Ceritinib
0.031623
ALK
RTK
 0.9788 0.00494
MDA-MB-231 Cabozantinib
0.031623
VEGFR2/MET
RTK
 0.9652 0.00580
MDA-MB-231 Cabozantinib
0.1
VEGFR2/MET
RTK
 0.9003 0.01079
HCC1806 Tivantinib
10.0
MET
RTK
 -0.2185 0.47523
Hs 578T Ceritinib
0.31623
ALK
RTK
 0.8074 0.04877
MDA-MB-231 Cabozantinib
10.0
VEGFR2/MET
RTK
 0.0749 0.20683
SK-BR-3 Ceritinib
0.001
ALK
RTK
 1.0870 0.01087
Hs 578T Ceritinib
1.0
ALK
RTK
 0.3515 0.17148
Hs 578T Ceritinib
10.0
ALK
RTK
 -0.4356 0.67418
Hs 578T Ceritinib
3.1623
ALK
RTK
 0.1599 0.22058
SK-BR-3 Ceritinib
0.1
ALK
RTK
 0.9793 -0.00117
HCC1806 Cediranib
0.0031623
VEGFR/cKIT
RTK
 1.0810 -0.01058
Hs 578T Neratinib
0.0031623
EGFR/HER2
RTK
 1.0284 0.00123
Hs 578T Tivantinib
0.01
MET
RTK
 0.9961 0.00485
SK-BR-3 Neratinib
0.00031623
EGFR/HER2
RTK
 0.8693 0.01462
HCC1806 Cediranib
0.031623
VEGFR/cKIT
RTK
 0.9721 0.00716
Hs 578T Neratinib
0.031623
EGFR/HER2
RTK
 1.0125 0.00436
Hs 578T Neratinib
0.01
EGFR/HER2
RTK
 0.9849 0.00721
SK-BR-3 Neratinib
0.031623
EGFR/HER2
RTK
 0.0194 0.21796
HCC1806 Cediranib
0.01
VEGFR/cKIT
RTK
 1.0401 0.00080
Hs 578T Neratinib
0.31623
EGFR/HER2
RTK
 0.6171 0.03083
SK-BR-3 Tivantinib
1.0
MET
RTK
 -0.3029 0.52635
SK-BR-3 Tivantinib
0.31623
MET
RTK
 0.4015 0.18097